Please Wait.....
Report
India Contract Development and Manufacturing Organization (CDMO) Market Report and Forecast 2025-2034
Market Report I 2025-06-20 I 250 Pages I EMR Inc.
The India contract development and manufacturing organization (CDMO) market was valued at USD 23.02 Billion in 2024 driven by large pool of skilled scientists, cost-effective manufacturing capabilities, and a well-established generic and biosimilars industry across the region. It is expected to grow at a CAGR of 10.80% during the forecast period of 2025-2034 and attain a market value of USD 64.20 Billion by 2034. In addition, the rising demand for complex biologics, global expansion strategies by Indian CDMOs, and increasing collaborations are driven by regulatory alignment with major markets like the U.S. and EU.
Indian CDMOs benefit from a long history in generic drug manufacturing, which has shaped a workforce skilled in process optimization, scale-up, and regulatory compliance. That foundation is now being applied to more advanced services, including biologics, cell and gene therapies, and niche formulations like antibody-drug conjugates (ADCs). As global demand for these therapies grows, Indian firms are investing in high-containment facilities, single-use bioreactors, and integrated R&D platforms to support the shift.
India Contract Development and Manufacturing Organization (CDMO) Market Overview
Contract development and manufacturing organizations (CDMOs) play a vital role in India's pharmaceutical and medical device industries by offering end-to-end services from research and development to commercial-scale manufacturing. They enable companies to reduce operational costs, accelerate product development, and comply with stringent global regulatory standards. With India's strong manufacturing capabilities, skilled workforce, and supportive policies, CDMOs attract both domestic and international clients. Their presence enhances innovation, efficiency, and global competitiveness, significantly contributing to the growth of India's life sciences sector. The market is expected to grow at a CAGR of 10.80% during the forecast period of 2025-2034 and attain a market value of USD 64.20 Billion by 2034.
What are the Drivers for India Contract Development and Manufacturing Organization (CDMO) Market Growth?
Programs Based on Strengthening India's Clinical Research and CDMO Capabilities to Boost Market Growth
In February 2025, Avance Clinical, an Australian CRO, established a specialized biometrics hub in Bangalore to enhance its GlobalReady program. This expansion focuses on statistical programming and data analytics to accelerate early-phase clinical trials for biotech companies in the United States and Australia. As demand for outsourced clinical research rises and India remains a hub for skilled talent and cost-effective services, this move is expected to elevate India's global standing in the CRO and CDMO markets during the forecast period.
Biologics Manufacturing Advancements to Meet Rising India Contract Development and Manufacturing Organization (CDMO) Market Demand
In January 2025, Shilpa Biologicals inaugurated a new bioconjugation manufacturing facility in Karnataka (a Southern state in India), joining the global league of CDMOs offering integrated antibody-drug conjugate (ADC) capabilities. This complements its existing cytotoxic fill-finish site in Hyderabad and positions India as a growing hub for complex biologics manufacturing. With increasing demand for high-quality, cost-efficient biologics production, such infrastructure upgrades are expected to attract international partnerships and boost the growth and global competitiveness of India's CDMO market.
What are the India Contract Development and Manufacturing Organization (CDMO) Market Trends?
The major market trends in the Indian CDMO market include rising global acquisitions and hybrid manufacturing models, enhancing value and development of the market.
Strategic Global Acquisitions Boosting India Contract Development and Manufacturing Organization (CDMO) Market Value
In June 2025, Zydus Lifesciences announced its entry into the global biologics CDMO sector with plans to acquire Agenus Inc.'s manufacturing facilities in the United States. The move allows Zydus to scale biologics production and enhance its global service capabilities. As Indian CDMOs increasingly pursue international acquisitions, such strategies are poised to elevate India's market value and global competitiveness in high-margin biologics outsourcing.
Hybrid CDMO Innovations Strengthening India Contract Development and Manufacturing Organization (CDMO) Market Size
In March 2024, Shilpa Medicare launched a new hybrid CDMO platform in New York. The model integrated development and commercial-scale manufacturing across biologics, synthetic small molecules, and complex generics. This aligns with India's growing focus on end-to-end CDMO solutions that meet global regulatory standards. The hybrid approach is expected to attract international partnerships, drive operational efficiency, and significantly strengthen India's CDMO market development during the forecast period.
What is the India Contract Development and Manufacturing Organization (CDMO) Market Segmentation?
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
- CRO
??- Clinical Services Preclinical Phase I Phase II Phase III Phase IV
??- Laboratory Services Analytical Services Bioanalytical Services
??- Chemistry, manufacturing and Controls (CMC)
??- Others
- CMO
??- Finished Dosage Formulation (FDF) Development and Manufacturing Solid Dose Formulation Liquid Dose Formulation Injectable Dose Formulation
??- Active Pharmaceutical Ingredient (API) Manufacturing High Potency (HPAPI) Large Molecule Small Molecule
Market Breakup by Application
- Oncological Disease
- Cardiovascular Disease
- Infectious Disease
- Others
Market Breakup by Region
- North India
- East and Central India
- West India
- South India
India Contract Development and Manufacturing Organization (CDMO) Market Share
Oncological Diseases to Lead the Market Share by Application
Oncological diseases are projected to hold the largest market share in India's contract development and manufacturing organization (CDMO) sector due to the escalating cancer burden and the growing demand for advanced therapeutics. In 2022, India reported approximately 1.46 million new cancer cases, with projections indicating an increase to 1.57 million by 2025, reflecting a 12.8% rise over five years. This surge underscores the urgent need for innovative cancer treatments. India's robust capabilities in developing and manufacturing complex generics, biosimilars, and antibody-drug conjugates attract global pharmaceutical companies seeking cost-effective oncology drug development. As per the analysis by Expert Market Research, the India biosimilar market is expected to grow at a CAGR of 14.20% during the forecast period of 2025-2034. In contrast, while cardiovascular and infectious diseases also contribute significantly, the complexity, investment, and innovation in oncology drug pipelines continue to drive the segment's dominance through the forecast period.
Who are the Leading Players in the India Contract Development and Manufacturing Organization (CDMO) Market?
The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Syngene International Limited
Established in 1993 and headquartered in Bangalore, India, Syngene International Limited is a leading contract research, development, and manufacturing organization (CRDMO). It offers integrated services across the drug development value chain, including discovery chemistry, biology, safety assessment, and commercial manufacturing. Syngene caters to global pharmaceutical, biotechnology, and agrochemical companies. Its state-of-the-art facilities and collaborations with major multinationals such as Bristol Myers Squibb reinforce its position as a key player in India's CDMO ecosystem.
Piramal Pharma Ltd.
Piramal Pharma Ltd., headquartered in Mumbai and established in 1988, is a global pharmaceutical company offering end-to-end contract development and manufacturing services. Through its CDMO division, Piramal Pharma Solutions, it supports drug substance and drug product development for small and large molecules. The company's portfolio spans clinical trial supply, API manufacturing, and sterile fill-finish. With facilities across North America, Europe, and India, Piramal is recognized for its regulatory compliance and scalable manufacturing capabilities.
Divi's Laboratories Ltd.
Founded in 1990 and headquartered in Hyderabad, Divi's Laboratories Ltd. is one of India's largest pharmaceutical manufacturing firms, focused on APIs, intermediates, and custom synthesis. With strong capabilities in complex chemistry and large-scale production, Divi's serves leading global pharma companies as a trusted CDMO partner. The company operates world-class manufacturing facilities and maintains high compliance with international regulatory standards, making it a major contributor to India's prominence in outsourced pharmaceutical development.
Laurus Synthesis Private Limited
Laurus Synthesis Private Limited, a subsidiary of Laurus Labs headquartered in Hyderabad and established in 2022, offers specialized contract research and manufacturing services. It focuses on custom synthesis, process development, and manufacturing of niche APIs and intermediates. With capabilities in high-potency APIs and complex chemistry, Laurus Synthesis supports early to late-stage development for pharmaceutical companies. The company's scientific expertise, regulatory focus, and modern infrastructure position it as a rising player in India's CDMO landscape.
Other key players in the market include Jubilant Pharmova Limited Company, Thermo Fisher Scientific Inc. (Patheon Pharma Services), Lonza Group AG, WuXi STA, AGC Biologics, Pfizer, Inc., and PCI Pharma Services.
Key Questions Answered in the India Contract Development and Manufacturing Organization (CDMO) Market
- What was the India contract development and manufacturing organization (CDMO) market value in 2024?
- What is the India contract development and manufacturing organization (CDMO) market forecast outlook for 2025-2034?
- What are the major factors aiding the India contract development and manufacturing organization (CDMO) market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major India contract development and manufacturing organization (CDMO) market trends?
- Which service type will lead the market segment?
- Which application will lead the market segment?
- Who are the key players involved in the India contract development and manufacturing organization (CDMO) market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Contract Development and Manufacturing Organization (CDMO) Market Overview
3.1 Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market
3.1.1 Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Historical Value (2018-2024)
3.1.2 Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Forecast Value (2025-2034)
3.2 India Contract Development and Manufacturing Organization (CDMO) Market
3.2.1 India Contract Development and Manufacturing Organization (CDMO) Market Historical Value (2018-2024)
3.2.2 India Contract Development and Manufacturing Organization (CDMO) Market Forecast Value (2025-2034)
4 India Contract Development and Manufacturing Organization (CDMO) Market Landscape
4.1 India Contract Development and Manufacturing Organization (CDMO) Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 India Contract Development and Manufacturing Organization (CDMO) Market: Service Landscape
4.2.1 Analysis By Service Type
4.2.2 Analysis By Application
5 India Contract Development and Manufacturing Organization (CDMO) Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 PESTEL Analysis
5.3.1 Political
5.3.2 Economic
5.3.3 Social
5.3.4 Technological
5.3.5 Legal
5.3.6 Environment
5.4 Porter's Five Forces Model
5.4.1 Bargaining Power of Suppliers
5.4.2 Bargaining Power of Buyers
5.4.3 Threat of New Entrants
5.4.4 Threat of Substitutes
5.4.5 Degree of Rivalry
5.5 Key Demand Indicators
5.6 Key Price Indicators
5.7 Industry Events, Initiatives, and Trends
5.8 Value Chain Analysis
6 India Contract Development and Manufacturing Organization (CDMO) Market Segmentation (218-2034)
6.1 India Contract Development and Manufacturing Organization (CDMO) Market (2018-2034) by Service Type
6.1.1 Market Overview
6.1.2 CRO
6.1.2.1 Clinical Services
6.1.2.1.1 Preclinical
6.1.2.1.2 Phase I
6.1.2.1.3 Phase II
6.1.2.1.4 Phase III
6.1.2.1.5 Phase IV
6.1.2.2 Laboratory Services
6.1.2.2.1 Analytical Services
6.1.2.2.2 Bioanalytical Services
6.1.2.3 Chemistry, manufacturing and Controls (CMC)
6.1.2.4 Others
6.1.3 CMO
6.1.3.1 Finished Dosage Formulation (FDF) Development and Manufacturing
6.1.3.1.1 Solid Dose Formulation
6.1.3.1.2 Liquid Dose Formulation
6.1.3.1.3 Injectable Dose Formulation
6.1.3.2 Active Pharmaceutical Ingredient (API) Manufacturing
6.1.3.2.1 High Potency (HPAPI)
6.1.3.2.2 Large Molecule
6.1.3.2.3 Small Molecule
6.2 India Contract Development and Manufacturing Organization (CDMO) Market (2018-2034) by Application
6.2.1 Market Overview
6.2.2 Oncological Disease
6.2.3 Cardiovascular Disease
6.2.4 Infectious Disease
6.2.5 Others
6.3 India Contract Development and Manufacturing Organization (CDMO) Market (2018-2034) by Region
6.3.1 Market Overview
6.3.2 North India
6.3.3 East and Central India
6.3.4 West India
6.3.5 South India
7 Regulatory Framework
8 Funding and Investment Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Strategic Initiatives
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Initiatives
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Supplier Landscape
10.1 Market Share Analysis (Top 5 Companies)
10.2 Syngene International Limited
10.2.1 Financial Analysis
10.2.2 Service Portfolio
10.2.3 Demographic Reach and Achievements
10.2.4 Company News and Developments
10.2.5 Certifications
10.3 Piramal Pharma Ltd.
10.3.1 Financial Analysis
10.3.2 Service Portfolio
10.3.3 Demographic Reach and Achievements
10.3.4 Company News and Developments
10.3.5 Certifications
10.4 Divi's Laboratories Ltd.
10.4.1 Financial Analysis
10.4.2 Service Portfolio
10.4.3 Demographic Reach and Achievements
10.4.4 Company News and Developments
10.4.5 Certifications
10.5 Laurus Synthesis Private Limited
10.5.1 Financial Analysis
10.5.2 Service Portfolio
10.5.3 Demographic Reach and Achievements
10.5.4 Company News and Developments
10.5.5 Certifications
10.6 Jubilant Pharmova Limited Company
10.6.1 Financial Analysis
10.6.2 Service Portfolio
10.6.3 Demographic Reach and Achievements
10.6.4 Company News and Developments
10.6.5 Certifications
10.7 Thermo Fisher Scientific Inc. (Patheon Pharma Services)
10.7.1 Financial Analysis
10.7.2 Service Portfolio
10.7.3 Demographic Reach and Achievements
10.7.4 Company News and Developments
10.7.5 Certifications
10.8 Lonza Group AG
10.8.1 Financial Analysis
10.8.2 Service Portfolio
10.8.3 Demographic Reach and Achievements
10.8.4 Company News and Developments
10.8.5 Certifications
10.9 WuXi STA
10.9.1 Financial Analysis
10.9.2 Service Portfolio
10.9.3 Demographic Reach and Achievements
10.9.4 Company News and Developments
10.9.5 Certifications
10.10 AGC Biologics
10.10.1 Financial Analysis
10.10.2 Service Portfolio
10.10.3 Demographic Reach and Achievements
10.10.4 Company News and Developments
10.10.5 Certifications
10.11 PCI Pharma Services
10.11.1 Financial Analysis
10.11.2 Service Portfolio
10.11.3 Demographic Reach and Achievements
10.11.4 Company News and Developments
10.11.5 Certifications
10.12 Pfizer, Inc.
10.12.1 Financial Analysis
10.12.2 Service Portfolio
10.12.3 Demographic Reach and Achievements
10.12.4 Company News and Developments
10.12.5 Certifications
11 Contract Development and Manufacturing Organization (CDMO) Market - Distribution Model (Additional Insight)
11.1 Overview
11.2 Potential Distributors
11.3 Key Parameters for Distribution Partner Assessment
12 Key Opinion Leaders (KOL) Insights (Additional Insight)
13 Payment Methods (Additional Insight)
13.1 Government Funded
13.2 Private Insurance
13.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security